Latest news and press releases about Bioventus Inc. (BVS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimula...
Price
| Price | $13.20 |
| Market Cap | $894M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 15.25 |
| Price / Book | 3.64 |
| EV / EBITDA | 12.06 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 28.39% |
| Return on Invested Capital | 11.37% |
| Return on Assets | 8.09% |
| Gross Margin | 68.00% |
| Operating Margin | 10.63% |
| Net Margin | 9.36% |
Related companies: AVNS · BFLY · CBLL · CTKB · KIDS · LAB · SMLR
Explore sector: Healthcare · Medical - Devices
More sections of BVS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks